Literature DB >> 20649802

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.

A Courpon-Claudinon1, A Lefort, X Panhard, O Clermont, Q Dornic, B Fantin, F Mentré, M Wolff, E Denamur, C Branger.   

Abstract

Escherichia coli is one of the major pathogens responsible for bactaeremia. Empirical antibiotherapy of these infections usually relies on third-generation cephalosporins (3GCs). Thus, the occurrence and epidemiology of 3GC-resistant strains have to be monitored. The French prospective multicentre study COLIBAFI collected 1081 strains of E. coli responsible for bacteraemia in 2005. In the present work, the prevalence of resistance to 3GCs was evaluated, and the implicated molecular mechanisms were characterized by specific PCR and sequencing. Phylogenetic grouping, O-typing, pulsed-field gel electrophoresis and virulence factor analysis were used to investigate the genetic background of the 3GC-resistant (3GC-R) strains. Clinical features of the patients with documented data (n = 1051) were analysed. Decreased susceptibility to 3GCs was observed in 41 strains (3.8%): 19, 18 and four had extended-spectrum β-lactamase (ESBL), AmpC cephalosporinase and OXA-type penicillinase phenotypes, respectively. Pulsed-field gel electrophoresis revealed that the 3GC-R strains constitute a diverse population. All but one of the strains with an ESBL phenotype produced a CTX-M-type enzyme, and six of them belonged to the widespread intercontinental clone O25b:H4-ST131. AmpC phenotype strains harboured various chromosomal ampC promoter and coding region mutations and/or the bla(CMY-2) plasmidic gene. 3GC-R strains carried fewer virulence factors and were more co-resistant to other antibiotics than 3GC-susceptible (3GC-S) strains. Infections with 3GC-R strains were mostly community-acquired and, as compared with those caused by their 3GC-S counterparts, were more severe. Underlying chronic disease and prior use of antibiotics were independent risk factors for development of a 3GC-R strain bacteraemia. The fact that the molecular support of 3GC resistance is mainly plasmid-mediated represents a potentially epidemic threat.
© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20649802     DOI: 10.1111/j.1469-0691.2010.03298.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  35 in total

1.  Impact of implementing French antibiotic guidelines for acute respiratory-tract infections in a paediatric emergency department, 2005-2009.

Authors:  F Angoulvant; D Skurnik; H Bellanger; H Abdoul; X Bellettre; L Morin; M Aptecar; G Galli-Gibertini; O Bourdon; C Doit; A Faye; J-C Mercier; R Cohen; C Alberti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-16       Impact factor: 3.267

Review 2.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.

Authors:  Y Matsumura; M Yamamoto; A Matsushima; M Nagao; Y Ito; S Takakura; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

4.  Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Authors:  Agnès Lefort; Xavière Panhard; Olivier Clermont; Paul-Louis Woerther; Catherine Branger; France Mentré; Bruno Fantin; Michel Wolff; Erick Denamur
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

5.  Genotypic-phenotypic discrepancies between antibiotic resistance characteristics of Escherichia coli isolates from calves in management settings with high and low antibiotic use.

Authors:  Margaret A Davis; Thomas E Besser; Lisa H Orfe; Katherine N K Baker; Amelia S Lanier; Shira L Broschat; Daniel New; Douglas R Call
Journal:  Appl Environ Microbiol       Date:  2011-03-18       Impact factor: 4.792

6.  Biofilm formation by and thermal niche and virulence characteristics of Escherichia spp.

Authors:  Danielle J Ingle; Olivier Clermont; David Skurnik; Erick Denamur; Seth T Walk; David M Gordon
Journal:  Appl Environ Microbiol       Date:  2011-02-18       Impact factor: 4.792

7.  Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.

Authors:  Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

Review 8.  Human and avian extraintestinal pathogenic Escherichia coli: infections, zoonotic risks, and antibiotic resistance trends.

Authors:  Melha Mellata
Journal:  Foodborne Pathog Dis       Date:  2013-08-20       Impact factor: 3.171

9.  Bloodstream infections caused by Escherichia coli producing AmpC β-lactamases: epidemiology and clinical features.

Authors:  V Pascual; N Alonso; M Simó; G Ortiz; M C Garcia; M Xercavins; A Rivera; M A Morera; E Miró; E Espejo; F Navarro; M Gurguí; J Pérez; M Rodríguez-Carballeira; J Garau; E Calbo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-22       Impact factor: 3.267

10.  Impact of "Raised without Antibiotics" Beef Cattle Production Practices on Occurrences of Antimicrobial Resistance.

Authors:  Amit Vikram; Pablo Rovira; Getahun E Agga; Terrance M Arthur; Joseph M Bosilevac; Tommy L Wheeler; Paul S Morley; Keith E Belk; John W Schmidt
Journal:  Appl Environ Microbiol       Date:  2017-10-31       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.